Drug Research, FDA Approval and Virus

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Drug Research

FDA Approval

Virus

ACTIV Update: Making Major Strides in COVID-19 Therapeutic Development

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy. And ACTIV has indeed moved at unprecedented speed since its launch.

Clinical Trials

Clinical Trials Trials Hospitals Vaccine

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

JANUARY 26, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Bamlanivimab FDA Approval History.

Hospitals

Hospitals Treatment Trials Long-Term Care Facilities

Drug Discovery Digest

ACTIV Update: Making Major Strides in COVID-19 Therapeutic Development

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

Stay Connected